Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Research Report 2023

Report ID: 1994708 | Published Date: Jan 2025 | No. of Page: 93 | Base Year: 2024 | Rating: 4.1 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Vitamin E & Pioglitazone
        1.2.3 Obeticholic Acid (OCA)
        1.2.4 Elafibranor
        1.2.5 Selonsertib & Cenicriviroc
    1.3 Market by Application
        1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Hospital Pharmacy
        1.3.3 Online Provider
        1.3.4 Retail Pharmacy
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered
2 Global Growth Trends
    2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2018-2029)
    2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Region
        2.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Region (2018-2023)
        2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Region (2024-2029)
    2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Dynamics
        2.3.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Trends
        2.3.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
        2.3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
        2.3.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue
        3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2018-2023)
        3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2018-2023)
    3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
    3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio
        3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2022
    3.5 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players Head office and Area Served
    3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
    3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Type
    4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2018-2023)
    4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2024-2029)
5 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Application
    5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2018-2023)
    5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2024-2029)
6 North America
    6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2029)
    6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
    6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada
7 Europe
    7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2029)
    7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
    7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2029)
    8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2018-2023)
    8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia
9 Latin America
    9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2029)
    9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
    9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2029)
    10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
    10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE
11 Key Players Profiles
    11.1 AstraZeneca
        11.1.1 AstraZeneca Company Detail
        11.1.2 AstraZeneca Business Overview
        11.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
        11.1.5 AstraZeneca Recent Development
    11.2 Conatus Pharmaceuticals
        11.2.1 Conatus Pharmaceuticals Company Detail
        11.2.2 Conatus Pharmaceuticals Business Overview
        11.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
        11.2.5 Conatus Pharmaceuticals Recent Development
    11.3 Enzo Biochem
        11.3.1 Enzo Biochem Company Detail
        11.3.2 Enzo Biochem Business Overview
        11.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
        11.3.5 Enzo Biochem Recent Development
    11.4 Galmed Pharmaceuticals
        11.4.1 Galmed Pharmaceuticals Company Detail
        11.4.2 Galmed Pharmaceuticals Business Overview
        11.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
        11.4.5 Galmed Pharmaceuticals Recent Development
    11.5 Genfit
        11.5.1 Genfit Company Detail
        11.5.2 Genfit Business Overview
        11.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
        11.5.5 Genfit Recent Development
    11.6 Gilead
        11.6.1 Gilead Company Detail
        11.6.2 Gilead Business Overview
        11.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
        11.6.5 Gilead Recent Development
    11.7 Horizon Pharma
        11.7.1 Horizon Pharma Company Detail
        11.7.2 Horizon Pharma Business Overview
        11.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
        11.7.5 Horizon Pharma Recent Development
    11.8 Immuron
        11.8.1 Immuron Company Detail
        11.8.2 Immuron Business Overview
        11.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
        11.8.5 Immuron Recent Development
    11.9 Intercept Pharmaceuticals
        11.9.1 Intercept Pharmaceuticals Company Detail
        11.9.2 Intercept Pharmaceuticals Business Overview
        11.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
        11.9.5 Intercept Pharmaceuticals Recent Development
    11.10 Novo Nordisk
        11.10.1 Novo Nordisk Company Detail
        11.10.2 Novo Nordisk Business Overview
        11.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
        11.10.5 Novo Nordisk Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Vitamin E & Pioglitazone
    Table 3. Key Players of Obeticholic Acid (OCA)
    Table 4. Key Players of Elafibranor
    Table 5. Key Players of Selonsertib & Cenicriviroc
    Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2018-2023) & (US$ Million)
    Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2018-2023)
    Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2024-2029)
    Table 12. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends
    Table 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
    Table 14. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
    Table 15. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
    Table 16. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2018-2023) & (US$ Million)
    Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players (2018-2023)
    Table 18. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2022)
    Table 19. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Companies by Revenue (US$ Million) in 2022
    Table 20. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (CR5 and HHI) & (2018-2023)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
    Table 23. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2018-2023) & (US$ Million)
    Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2018-2023)
    Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2024-2029)
    Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2018-2023) & (US$ Million)
    Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2018-2023)
    Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2024-2029)
    Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
    Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2029) & (US$ Million)
    Table 36. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 37. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
    Table 38. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2029) & (US$ Million)
    Table 39. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 40. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2018-2023) & (US$ Million)
    Table 41. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2024-2029) & (US$ Million)
    Table 42. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 43. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
    Table 44. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 46. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
    Table 47. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2029) & (US$ Million)
    Table 48. AstraZeneca Company Detail
    Table 49. AstraZeneca Business Overview
    Table 50. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 51. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
    Table 52. AstraZeneca Recent Development
    Table 53. Conatus Pharmaceuticals Company Detail
    Table 54. Conatus Pharmaceuticals Business Overview
    Table 55. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 56. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
    Table 57. Conatus Pharmaceuticals Recent Development
    Table 58. Enzo Biochem Company Detail
    Table 59. Enzo Biochem Business Overview
    Table 60. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 61. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
    Table 62. Enzo Biochem Recent Development
    Table 63. Galmed Pharmaceuticals Company Detail
    Table 64. Galmed Pharmaceuticals Business Overview
    Table 65. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 66. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
    Table 67. Galmed Pharmaceuticals Recent Development
    Table 68. Genfit Company Detail
    Table 69. Genfit Business Overview
    Table 70. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 71. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
    Table 72. Genfit Recent Development
    Table 73. Gilead Company Detail
    Table 74. Gilead Business Overview
    Table 75. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 76. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
    Table 77. Gilead Recent Development
    Table 78. Horizon Pharma Company Detail
    Table 79. Horizon Pharma Business Overview
    Table 80. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 81. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
    Table 82. Horizon Pharma Recent Development
    Table 83. Immuron Company Detail
    Table 84. Immuron Business Overview
    Table 85. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 86. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
    Table 87. Immuron Recent Development
    Table 88. Intercept Pharmaceuticals Company Detail
    Table 89. Intercept Pharmaceuticals Business Overview
    Table 90. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 91. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
    Table 92. Intercept Pharmaceuticals Recent Development
    Table 93. Novo Nordisk Company Detail
    Table 94. Novo Nordisk Business Overview
    Table 95. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 96. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
    Table 97. Novo Nordisk Recent Development
    Table 98. Research Programs/Design for This Report
    Table 99. Key Data Information from Secondary Sources
    Table 100. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type: 2022 VS 2029
    Figure 3. Vitamin E & Pioglitazone Features
    Figure 4. Obeticholic Acid (OCA) Features
    Figure 5. Elafibranor Features
    Figure 6. Selonsertib & Cenicriviroc Features
    Figure 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2022 VS 2029
    Figure 9. Hospital Pharmacy Case Studies
    Figure 10. Online Provider Case Studies
    Figure 11. Retail Pharmacy Case Studies
    Figure 12. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered
    Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 15. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region: 2022 VS 2029
    Figure 16. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players in 2022
    Figure 17. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2022)
    Figure 18. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2022
    Figure 19. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 20. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2029)
    Figure 21. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 22. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 23. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 24. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2029)
    Figure 25. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 28. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2018-2029)
    Figure 33. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 40. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2029)
    Figure 41. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2029)
    Figure 45. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 47. AstraZeneca Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
    Figure 48. Conatus Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
    Figure 49. Enzo Biochem Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
    Figure 50. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
    Figure 51. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
    Figure 52. Gilead Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
    Figure 53. Horizon Pharma Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
    Figure 54. Immuron Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
    Figure 55. Intercept Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
    Figure 56. Novo Nordisk Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
    Figure 57. Bottom-up and Top-down Approaches for This Report
    Figure 58. Data Triangulation
    Figure 59. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
Frequently Asked Questions
Non-Alcoholic Steatohepatitis (NASH) Drugs report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Non-Alcoholic Steatohepatitis (NASH) Drugs report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Non-Alcoholic Steatohepatitis (NASH) Drugs report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Over-the-Top (OTT)

This report aims to provide a comprehensive presentation of the global market for Over-the-Top (O ... Read More